絞り込み

16555

広告

職員以外も加算 ケアマネなど、処遇改善 (毎日新聞)

厚生労働省は15日、来年10月の消費増税に合わせた介護職員の処遇改善策について、介護報酬の加算分を介護職員以外の職種の給与増に使うことを認める方針を示した。対象...

  1. 温暖化でビール高値に 大麦の収穫減で -...
  2. 温暖化でビール高値に - 徳島新聞
  3. 温暖化でビール高値に (デイリースポーツ...
  4. 温暖化でビール高値に 大麦の収穫減、今世...

ニュース一覧

Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report.

著者 Bruno R , Proietti A , Alì G , Puppo G , Ribechini A , Chella A , Fontanini G
Oncol Lett.2017 Nov ; 14(5):5947-5951.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (70view , 0users)

Full Text Sources

Miscellaneous

The present case report describes the infrequent coexistence of squamous cell transformation and the epidermal growth factor receptor (EGFR) T790M mutation as resistance mechanisms to first line treatment with tyrosine kinase inhibitors. The patient was a 44-year-old female, diagnosed with a primitive advanced lung adenocarcinoma with bone metastases. The tumor was positive for the EGFR exon 19 deletion, therefore the patient was treated with afatinib (40 mg/day, orally) and radiotherapy for bone lesions. After 16 months, the patient developed resistance. Cytological examination of the pleural effusion confirmed an adenocarcinoma positive for the EGFR exon 19 deletion and the T790M mutation within exon 20, while a biopsy from the upper left bronchus revealed a keratinizing squamous cell carcinoma positive for the EGFR exon 19 deletion. In addition, the EGFR mutations were concomitantly detected in circulating cell-free tumour DNA. Due to the presence of the T790M mutation, the patient underwent osimertinib therapy (80 mg/day, orally), which resulted in a partial tumour regression at the 2-month follow-up, whereas the squamous lesions were treated with radiotherapy. The adenocarcinoma and squamous carcinoma components may share the same origin, according to the presence of the EGFR exon 19 deletion in both lesions. More accurate characterization of resistance mechanisms may lead to the development of improved treatment regimens.
PMID: 29113230 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード